XenoTherapeutics Overview
- Year Founded
-
2016
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Debt - Acquisition
- (Announced)
- Investors
-
4
XenoTherapeutics General Information
Description
Operator of a biotechnology research and development company intended to further the advancement of the science of xenotransplantation through education, research, development, and clinical testing. The company focuses on product discovery and testing to de-risk and optimize therapeutic candidates while decreasing the time to market, enabling medical researchers to get access to an affordable, safe, and plentiful treatment whenever necessary.
Contact Information
Website
www.xenotx.orgCorporate Office
- Greater Boston Area
- Boston, MA
- United States
Corporate Office
- Greater Boston Area
- Boston, MA
- United States
XenoTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Debt - Acquisition | 14-Jul-2025 | Announced | Clinical Trials - General | |||
| 4. Later Stage VC (Series A) | 17-May-2021 | Completed | Clinical Trials - General | |||
| 3. Accelerator/Incubator | 01-Jan-2018 | Completed | Startup | |||
| 2. Grant | 27-Jan-2017 | $10K | Completed | Clinical Trials - General | ||
| 1. Accelerator/Incubator | 19-May-2016 | Completed | Startup |
XenoTherapeutics Comparisons
Industry
Financing
Details
XenoTherapeutics Competitors (4)
One of XenoTherapeutics’s 4 competitors is ITB-Med, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ITB-Med | Venture Capital-Backed | New York, NY | ||||
| Egenesis | Venture Capital-Backed | Cambridge, MA | ||||
| ProKidney | Corporation | Winston-Salem, NC | ||||
| United Therapeutics | Formerly VC-backed | Silver Spring, MD |
XenoTherapeutics Patents
XenoTherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2022256401-A1 | Xenogeneic nerve transplants and methods | Inactive | 01-Jun-2021 | ||
| US-20260114433-A1 | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human beta2-microglobulin within donor cells, tissues, or organs | Inactive | 16-Dec-2020 | ||
| WO-2022133155-A1 | Humanization of beta2-microglobulin in porcine genome resulting in functional expression of human βeta2-microglobulin within donor cells, tissues, or organs | Inactive | 16-Dec-2020 | ||
| AU-2021333671-A1 | Immunologically compatible cells, tissues, organs, and methods for transplantation for silencing, humanization, and personalization with minimized collateral genomic disruptions | Inactive | 24-Aug-2020 | ||
| AU-2021333671-A9 | Immunologically compatible cells, tissues, organs, and methods for transplantation for silencing, humanization, and personalization with minimized collateral genomic disruptions | Inactive | 24-Aug-2020 | A01K67/0275 |
XenoTherapeutics Signals
XenoTherapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Varana Capital | PE/Buyout | Minority | ||
| Mass Innovation Network | Accelerator/Incubator | |||
| John Flatley Company | Corporation | |||
| MassChallenge | Accelerator/Incubator |
XenoTherapeutics Acquisitions (2)
XenoTherapeutics’s most recent deal was a Merger/Acquisition with Repare Therapeutics for . The deal was made on 28-Jan-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Repare Therapeutics | 28-Jan-2026 | Merger/Acquisition | Drug Discovery | ||
| ESSA Pharma | 09-Oct-2025 | Merger/Acquisition | Drug Discovery |
XenoTherapeutics Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Repare Therapeutics | Saint-Laurent, Canada | 2016 |
XenoTherapeutics FAQs
-
When was XenoTherapeutics founded?
XenoTherapeutics was founded in 2016.
-
Where is XenoTherapeutics headquartered?
XenoTherapeutics is headquartered in Boston, MA.
-
What is the size of XenoTherapeutics?
XenoTherapeutics has 10 total employees.
-
What industry is XenoTherapeutics in?
XenoTherapeutics’s primary industry is Drug Discovery.
-
Is XenoTherapeutics a private or public company?
XenoTherapeutics is a Private company.
-
What is XenoTherapeutics’s current revenue?
The current revenue for XenoTherapeutics is .
-
Who are XenoTherapeutics’s investors?
Varana Capital, Mass Innovation Network, John Flatley Company, and MassChallenge have invested in XenoTherapeutics.
-
Who are XenoTherapeutics’s competitors?
ITB-Med, Egenesis, ProKidney, and United Therapeutics are competitors of XenoTherapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process